Search Within

Saad Zafar Usmani

  1. "CTCR Scholars"
Formats
  1. Meeting Abstract (76)
  2. Journal Article (19)
  3. Research Letter (5)
  4. Correspondence (2)
Groups
  1. CTCR Scholars (102)
  2. Department of Medicine (102)
  3. Hematologic Malignancies, Division of (102)
  4. Center for Hematologic Malignancies (100)
  5. Myeloma (99)
  6. Hematologic Malignancies Research (98)

More Groups

People
  1. Urvi Shah (99)
  2. Alexander Lesokhin (97)
  3. Sham Mailankody (90)
  4. Carlyn Rose Tan (87)
  5. Malin Hultcrantz (87)
  6. Hani Hassoun (86)

More People

Years
  1. 2025 (3)
  2. 2024 (34)
  3. 2023 (40)
  4. 2022 (25)
Publications
  1. Blood (33)
  2. Clinical Lymphoma, Myeloma and Leukemia (33)
  3. Journal of Clinical Oncology (12)
  4. Blood Advances (6)
  5. Blood Cancer Journal (6)
  6. American Journal of Hematology (2)

More Publications

Publishers
  1. American Society of Hematology (39)
  2. Elsevier Inc. (34)
  3. American Society of Clinical Oncology (12)
  4. Nature Publishing Group (7)
  5. John Wiley & Sons, Inc. (2)
  6. Massachusetts Medical Society (2)

More Publishers

Results (102)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save